<?xml version='1.0' encoding='utf-8'?>
<document id="24250287"><sentence text="Probe substrate and enzyme source-dependent inhibition of UDP-glucuronosyltransferase (UGT) 1A9 by wogonin."><entity charOffset="99-106" id="DDI-PubMed.24250287.s1.e0" text="wogonin" /></sentence><sentence text="Drug-metabolizing enzymes (DMEs) inhibition based drug-drug interaction and herb-drug interaction severely challenge the R&amp;D process of drugs or herbal ingredients" /><sentence text="" /><sentence text="To evaluate the inhibition potential of wogonin (an important flavonoid isolated from the root of Scutellaria baicalensis) towards one of the most important phase II DMEs, UDP-glucuronosyltransferase (UGT) 1A9"><entity charOffset="40-47" id="DDI-PubMed.24250287.s4.e0" text="wogonin" /><entity charOffset="62-71" id="DDI-PubMed.24250287.s4.e1" text="flavonoid" /><pair ddi="false" e1="DDI-PubMed.24250287.s4.e0" e2="DDI-PubMed.24250287.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24250287.s4.e0" e2="DDI-PubMed.24250287.s4.e1" /></sentence><sentence text="" /><sentence text="Both recombinant UGT1A9-catalyzed 4-methylumbelliferone (4-MU) glucuronidation reaction and human liver microsomes (HLMs)-catalyzed propofol glucuronidation reaction were used as two different probe reactions"><entity charOffset="34-55" id="DDI-PubMed.24250287.s6.e0" text="4-methylumbelliferone" /><entity charOffset="57-61" id="DDI-PubMed.24250287.s6.e1" text="4-MU" /><entity charOffset="132-140" id="DDI-PubMed.24250287.s6.e2" text="propofol" /><pair ddi="false" e1="DDI-PubMed.24250287.s6.e0" e2="DDI-PubMed.24250287.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24250287.s6.e0" e2="DDI-PubMed.24250287.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24250287.s6.e0" e2="DDI-PubMed.24250287.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24250287.s6.e1" e2="DDI-PubMed.24250287.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24250287.s6.e1" e2="DDI-PubMed.24250287.s6.e2" /></sentence><sentence text="" /><sentence text="Wogonin noncompetitively inhibited recombinant UGT1A9-catalyzed 4-MU glucuronidation, and exerted competitive inhibition towards HLMs-catalyzed propofol glucuronidation"><entity charOffset="144-152" id="DDI-PubMed.24250287.s8.e0" text="propofol" /><entity charOffset="64-71" id="DDI-PubMed.24250287.s8.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.24250287.s8.e1" e2="DDI-PubMed.24250287.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24250287.s8.e1" e2="DDI-PubMed.24250287.s8.e0" /></sentence><sentence text=" The inhibition kinetic parameters (Ki) were calculated to be 3" /><sentence text="2 µM and 52" /><sentence text="0µM, respectively" /><sentence text="" /><sentence text="Necessary monitoring was needed when wogonin was co-administered with the clinical drugs mainly undergoing UGT1A9-mediated glucuronidation elimination"><entity charOffset="37-44" id="DDI-PubMed.24250287.s13.e0" text="wogonin" /></sentence><sentence text=" Additionally, probe reactions-dependent inhibition of wogonin towards the activity of UGT1A9 should be paid attention when translating these in vitro data into in vivo situation"><entity charOffset="55-62" id="DDI-PubMed.24250287.s14.e0" text="wogonin" /></sentence><sentence text="" /></document>